Emergent Biosolutions Share Price (NYSE: EBS)

$8.59

▲

-0.12

(-1.38%)

Last updated on August 28, 2025 at 11:36 pm IST

$₹

Check the interactive Emergent Biosolutions Stock chart to analyse performance

Emergent Biosolutions stock performance

as on August 28, 2025 at 11:36 pm IST

Today's Low:$8.57
Today's High:$8.89
$8.59
0.23%
Downside
Day's Volatility :3.6%
Upside
3.37%
52 Weeks Low:$4.02
52 Weeks High:$12.73
$8.59
53.2%
Downside
52 Weeks Volatility :68.42%
Upside
32.52%

Emergent Biosolutions Stock Returns

Period	Emergent Biosolutions Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	32.97%	4.2%	0.0%
6 Months	21.67%	-8.0%	0.0%
1 Year	-3.59%	-12.1%	0.0%
3 Years	-65.1%	7.6%	-6.9%

Emergent Biosolutions Inc Key Stats

Check Emergent Biosolutions key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$8.59
Open	$8.84
Today's High	$8.68
Today's Low	$8.37
Market Capitalization	$464.7M
Today's Volume	$655.3K
52 Week High	$12.73
52 Week Low	$4.02
Revenue TTM	$851.6M
EBITDA	$216.8M
Earnings Per Share (EPS)	$2.62
PE Ratio	3.32
Profit Margin	16.38%
Quarterly Earnings Growth YOY	6.0%
Return On Equity TTM	30.24%

Stock Returns calculator for Emergent Biosolutions Stock including INR - Dollar returns

The Emergent Biosolutions stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Emergent Biosolutions investment value today

Current value as on today

₹1,00,768

Returns

₹768

(+0.77%)

Returns from Emergent Biosolutions Stock

₹3,591 (-3.59%)

Dollar Returns*

₹4,360 (+4.36%)

Indian investors sentiment towards Emergent Biosolutions Stock

-33%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Search interest for Emergent Biosolutions Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Emergent Biosolutions Inc

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
6.72%
Millennium Management LLC
4.69%
American Century Companies Inc
4.30%
Dimensional Fund Advisors, Inc.
3.47%
BlackRock Inc
3.44%
State Street Corp
3.21%

Analyst Recommendation on Emergent Biosolutions Stock

Rating

Trend

Sell

11%Buy

22%Hold

66%Sell

Based on 9 Wall street analysts offering stock ratings for Emergent Biosolutions(by analysts ranked 0 to 5 stars)

Emergent Biosolutions Share Price Target

What analysts predicted

Upside of 57.16%

Target:

$13.50

Current:

$8.59

Emergent Biosolutions share price target is $13.50, a slight Upside of 57.16% compared to current price of $8.59 as per analysts' prediction.

Emergent Biosolutions Stock Insights

Price Movement
In the last 7 days, EBS stock has moved down by -7.8%
Decreasing Revenue
Revenue is down for the last 2 quarters, 222.2M → 140.9M (in $), with an average decrease of 36.6% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 68.0M → -12.0M (in $), with an average decrease of 117.7% per quarter
EBS vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 11.6% return, outperforming this stock by 15.2%
EBS vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 31.7% return, outperforming this stock by 98.2%
Price to Sales
ForEBS every $1 of sales, investors are willing to pay $0.5, whereas for Neurocrine Biosciences Inc., the investors are paying $5.5 for every $1 of sales.

Emergent Biosolutions Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.1B	↑ 41.36%
Net Income	$54.5M	↓ 13.08%
Net Profit Margin	4.93%	↓ 3.08%

	FY20	Y/Y Change
Revenue	$1.6B	↑ 40.63%
Net Income	$305.8M	↑ 461.1%
Net Profit Margin	19.66%	↑ 14.73%

	FY21	Y/Y Change
Revenue	$1.8B	↑ 15.26%
Net Income	$219.5M	↓ 28.22%
Net Profit Margin	12.24%	↓ 7.42%

	FY22	Y/Y Change
Revenue	$1.1B	↓ 37.47%
Net Income	$-223.8M	↓ 201.96%
Net Profit Margin	-19.97%	↓ 32.21%

	FY23	Y/Y Change
Revenue	$1.0B	↓ 6.39%
Net Income	$-760.5M	↑ 239.81%
Net Profit Margin	-72.48%	↓ 52.51%

	FY24	Y/Y Change
Revenue	$1.0B	↓ 3.4%
Net Income	$-190.6M	↓ 74.94%
Net Profit Margin	-18.8%	↑ 53.68%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$300.4M	↑ 8.6%
Net Income	$9.0M	↓ 118.18%
Net Profit Margin	3.0%	↑ 20.9%

	Q2 FY24	Q/Q Change
Revenue	$254.7M	↓ 15.21%
Net Income	$-283.1M	↓ 3245.56%
Net Profit Margin	-111.15%	↓ 114.15%

	Q3 FY24	Q/Q Change
Revenue	$293.8M	↑ 15.35%
Net Income	$114.8M	↓ 140.55%
Net Profit Margin	39.07%	↑ 150.22%

	Q4 FY24	Q/Q Change
Revenue	$189.3M	↓ 35.57%
Net Income	$-31.3M	↓ 127.26%
Net Profit Margin	-16.53%	↓ 55.6%

	Q1 FY25	Q/Q Change
Revenue	$222.2M	↑ 17.38%
Net Income	$68.0M	↓ 317.25%
Net Profit Margin	30.6%	↑ 47.13%

	Q2 FY25	Q/Q Change
Revenue	$140.9M	↓ 36.59%
Net Income	$-12.0M	↓ 117.65%
Net Profit Margin	-8.52%	↓ 39.12%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$672.5M	↑ 46.16%

	FY20	Y/Y Change
Profit	$1.0B	↑ 53.37%

	FY21	Y/Y Change
Profit	$1.0B	↑ 0.37%

	FY22	Y/Y Change
Profit	$427.2M	↓ 58.73%

	FY23	Y/Y Change
Profit	$343.9M	↓ 19.5%

	FY24	Y/Y Change
Profit	$305.2M	↓ 11.25%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$139.4M	↑ 86.36%

	Q2 FY24	Q/Q Change
Profit	$-54.5M	↓ 139.1%

	Q3 FY24	Q/Q Change
Profit	$164.2M	↓ 401.28%

	Q4 FY24	Q/Q Change
Profit	$60.0M	↓ 63.46%

	Q1 FY25	Q/Q Change
Profit	$133.7M	↑ 122.83%

	Q2 FY25	Q/Q Change
Profit	$57.8M	↓ 56.77%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$188.0M	↑ 349.76%
Investing Cash Flow	$-96.9M	↓ 89.2%
Financing Cash Flow	$-35.9M	↓ 104.55%

	FY20	Y/Y Change
Operating Cash Flow	$536.0M	↑ 185.11%
Investing Cash Flow	$-151.0M	↑ 55.83%
Financing Cash Flow	$69.5M	↓ 293.59%

	FY21	Y/Y Change
Operating Cash Flow	$321.1M	↓ 40.09%
Investing Cash Flow	$-225.0M	↑ 49.01%
Financing Cash Flow	$-141.0M	↓ 302.88%

	FY22	Y/Y Change
Operating Cash Flow	$-34.1M	↓ 110.62%
Investing Cash Flow	$-381.3M	↑ 69.47%
Financing Cash Flow	$481.2M	↓ 441.28%

	FY23	Y/Y Change
Operating Cash Flow	$-206.3M	↑ 504.99%
Investing Cash Flow	$212.3M	↓ 155.68%
Financing Cash Flow	$-535.7M	↓ 211.33%

	FY24	Y/Y Change
Operating Cash Flow	$58.7M	↓ 128.45%
Investing Cash Flow	$125.2M	↓ 41.03%
Financing Cash Flow	$-190.0M	↓ 64.53%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-62.6M	↓ 295.02%
Investing Cash Flow	$-10.8M	↓ 5.26%
Financing Cash Flow	$40.7M	↑ 765.96%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$47.5M	↓ 175.88%
Investing Cash Flow	$-4.6M	↓ 57.41%
Financing Cash Flow	$-50.9M	↓ 225.06%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$153.7M	↑ 223.58%
Investing Cash Flow	$112.0M	↓ 2534.78%
Financing Cash Flow	$-180.3M	↑ 254.22%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-79.9M	↓ 151.98%
Investing Cash Flow	$28.6M	↓ 74.46%
Financing Cash Flow	$500.0K	↓ 100.28%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-11.2M	↓ 85.98%
Investing Cash Flow	$59.5M	↑ 108.04%
Financing Cash Flow	$-400.0K	↓ 180.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$106.4M	↓ 1050.0%
Investing Cash Flow	$17.2M	↓ 71.09%
Financing Cash Flow	$-6.4M	↑ 1500.0%

Emergent Biosolutions Technicals Summary

Sell

Neutral

Buy

Emergent Biosolutions is currently in a neutral trading position according to technical analysis indicators.

Emergent Biosolutions Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Emergent Biosolutions Inc	32.15%	21.67%	-3.59%	-65.1%	-92.47%
Haleon Plc Spon Ads	-1.02%	-0.82%	-2.8%	59.97%	31.04%
United Therapeutics Corporation	2.62%	-5.65%	-15.14%	40.39%	71.72%
Zoetis Inc.	2.89%	-5.82%	-15.06%	-1.58%	-2.95%
Neurocrine Biosciences Inc.	2.94%	17.55%	11.61%	31.15%	18.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Emergent Biosolutions Inc	3.32	3.32	1.55	1.19	0.3	0.05	NA	9.99
Haleon Plc Spon Ads	21.4	21.4	3.13	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.91	11.91	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.69	26.69	2.51	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	40.49	40.49	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Emergent Biosolutions Inc	Sell	$464.7M	-92.47%	3.32	16.38%
Haleon Plc Spon Ads	Buy	$43.9B	31.04%	21.4	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.72%	11.91	40.36%
Zoetis Inc.	Buy	$68.6B	-2.95%	26.69	27.83%
Neurocrine Biosciences Inc.	Buy	$13.6B	18.65%	40.49	13.88%

About Emergent Biosolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Organization	Emergent Biosolutions
Employees	900
CEO	Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
Industry	Health Technology

Key Management of Emergent Biosolutions Inc

Name	Title
Mr. Joseph C. Papa Jr., M.B.A., R.Ph.	CEO, President & Director
Mr. Richard S. Lindahl M.B.A.	Executive VP, CFO & Treasurer
Ms. Coleen Glessner	Executive Vice President of Quality, Ethics & Compliance
Mr. Paul A. Williams	Senior Vice President of Products Business
Mr. William Hartzel	Senior Vice President of Manufacturing & Bioservices
Ms. Jessica Perl	Senior VP, Corporate Secretary & General Counsel
Ms. Michelle Pepin	Senior VP & Chief Human Resource Officer
Ms. Stephanie Duatschek	Chief Global Strategy & Franchise Development Officer
Mr. Simon C. Lowry M.D.	Chief Medical Officer and Head of Research & Development

Important FAQs about investing in EBS Stock from India :

What is Emergent Biosolutions share price today?

Emergent Biosolutions share price today is $8.59 as on August 28, 2025 at 11:36 pm IST at the close of the market. Emergent Biosolutions share today touched a day high of $8.89 and a low of $8.57.

What is the 52 week high and 52 week low for Emergent Biosolutions share?

Emergent Biosolutions share touched a 52 week high of $12.73 and a 52 week low of $4.02. Emergent Biosolutions stock price today i.e. August 28, 2025 at 11:36 pm IST is closed at $8.59, lower by 32.52% versus the 52 week high.

How to invest in Emergent Biosolutions Stock (EBS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Emergent Biosolutions on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Emergent Biosolutions Shares that will get you 0.1746 shares as per Emergent Biosolutions share price of $8.59 per share as on August 28, 2025 at 11:36 pm IST.

What is the minimum amount required to buy Emergent Biosolutions Stock (EBS) from India?

Indian investors can start investing in Emergent Biosolutions (EBS) shares with as little as ₹87.587 or $1 (as of August 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.87 in Emergent Biosolutions stock (as per the Rupee-Dollar exchange rate as on August 28, 2025). Based on Emergent Biosolutions share’s latest price of $8.59 as on August 28, 2025 at 11:36 pm IST, you will get 1.1641 shares of Emergent Biosolutions. Learn more about fractional shares .

What are the returns that Emergent Biosolutions has given to Indian investors in the last 5 years?

Emergent Biosolutions stock has given -92.47% share price returns and 18.52% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?